Alpha-Synuclein
A small, abundant protein with a normal job - until it misfolds, spreads, and dismantles the neurons that make dopamine.
Meet the Molecular Villain
Every great crime story has a protagonist who seems perfectly ordinary until something goes wrong. Alpha-synuclein is that protagonist. It is one of the most abundant proteins in the brain, making up roughly 1% of all cytosolic proteinin neurons, and for most of a person's life it performs a quiet, useful function at the synaptic terminal.
But alpha-synuclein is also unusually prone to misfolding. When it does, the consequences cascade outward: misfolded copies recruit healthy copies, toxic clusters form, neurons begin to fail, and the misfolded protein escapes to neighbouring cells and repeats the cycle.
The dense clumps it eventually forms - Lewy bodies - became the defining hallmark of Parkinson's disease decades ago. But as the science has advanced, researchers have realised that Lewy bodies may be more the crime scene than the cause of death. The real damage happens much earlier.
What this actually means
Alpha-synuclein is a very common brain protein that normally does useful work. But it can change into the wrong shape, stick to other copies of itself, and spread from cell to cell, damaging neurons along the way.
Picture this: Imagine a single piece of origami that gets crumpled. The crumpled version touches a flat sheet and crumples that one too -- soon the whole stack is ruined, one sheet at a time.
Why it matters: This protein is at the heart of what goes wrong in Parkinson's. Understanding it is the first step to understanding the disease itself.
Meet the Molecular Villain
Every great crime story has a protagonist who seems perfectly ordinary until something goes wrong. Alpha-synuclein is that protagonist. It is one of the most abundant proteins in the brain, making up roughly 1% of all cytosolic proteinin neurons, and for most of a person's life it performs a quiet, useful function at the synaptic terminal.
But alpha-synuclein is also unusually prone to misfolding. When it does, the consequences cascade outward: misfolded copies recruit healthy copies, toxic clusters form, neurons begin to fail, and the misfolded protein escapes to neighbouring cells and repeats the cycle.
The dense clumps it eventually forms - Lewy bodies - became the defining hallmark of Parkinson's disease decades ago. But as the science has advanced, researchers have realised that Lewy bodies may be more the crime scene than the cause of death. The real damage happens much earlier.
What Alpha-Synuclein Normally Does
Think of alpha-synuclein as a traffic coordinator at a busy shipping dock. At the presynaptic terminal, it helps organise the clustering of synaptic vesicles and facilitates their fusion with the membrane - the step that releases neurotransmitters into the synapse.
More specifically, healthy alpha-synuclein interacts with the SNARE complex - the molecular machinery that docks and fuses vesicles - and is thought to act as a chaperone that keeps SNARE proteins in the right conformation for repeated rounds of vesicle release.
It is an intrinsically disordered protein: it has no fixed three-dimensional shape in solution, instead adopting different conformations depending on its environment. This structural flexibility is what gives it functional versatility - and also what makes it so prone to adopting dangerous shapes when conditions change.
By the numbers
- 140 amino acids long
- 14.46 kDa molecular weight
- ~1% of total brain cytosolic protein
- Especially concentrated in presynaptic terminals
What this actually means
In its healthy state, alpha-synuclein helps brain cells send signals by managing tiny packages of chemical messengers at the connection point between neurons.
Picture this: Think of it as a dock worker loading and launching cargo boats (vesicles) across a narrow river (the synapse). Without it, boats pile up and deliveries stall.
Why it matters: The protein's normal job is important for smooth brain communication. Its flexible, shape-shifting nature is what makes it useful -- but also what makes it vulnerable to going wrong.
Common misconception: Alpha-synuclein is not a 'bad' protein. It performs essential functions; the problem is when it changes shape and clumps together.
What Alpha-Synuclein Normally Does
Think of alpha-synuclein as a traffic coordinator at a busy shipping dock. At the presynaptic terminal, it helps organise the clustering of synaptic vesicles and facilitates their fusion with the membrane - the step that releases neurotransmitters into the synapse.
More specifically, healthy alpha-synuclein interacts with the SNARE complex - the molecular machinery that docks and fuses vesicles - and is thought to act as a chaperone that keeps SNARE proteins in the right conformation for repeated rounds of vesicle release.
It is an intrinsically disordered protein: it has no fixed three-dimensional shape in solution, instead adopting different conformations depending on its environment. This structural flexibility is what gives it functional versatility - and also what makes it so prone to adopting dangerous shapes when conditions change.
By the numbers
- 140 amino acids long
- 14.46 kDa molecular weight
- ~1% of total brain cytosolic protein
- Especially concentrated in presynaptic terminals
The Misfolding Cascade
Misfolding does not happen all at once. It progresses through distinct stages, each with different structural properties and different degrees of toxicity. Understanding the sequence matters because different stages represent different therapeutic targets.
Healthy Monomer
In its normal state, alpha-synuclein is an intrinsically disordered 140-amino-acid protein (14.46 kDa) that adopts a loose, flexible structure. It concentrates at presynaptic terminals where it helps regulate vesicle release.
Early Misfolding
Under stress - oxidative damage, mutations, metal ions, or simply high local concentration - the monomer begins folding incorrectly, exposing hydrophobic regions normally tucked inside the structure.
Oligomers
Misfolded monomers cluster together into small, soluble oligomers of 10–50 units. This is widely considered the most neurotoxic stage: oligomers punch pores in cell membranes, disrupt calcium signalling, and impair mitochondria.
Protofibrils
Oligomers elongate into curved, ring-shaped or linear protofibrils. These structures begin acquiring the characteristic beta-sheet-rich core of mature amyloid fibrils and can still cross membranes.
Mature Fibrils
Protofibrils mature into straight, stable amyloid fibrils with a highly ordered beta-sheet spine. Fibrils are less acutely toxic than oligomers but serve as seeds for recruiting healthy protein into the misfolding cascade.
Lewy Body
Fibrils, along with lipids, organelle fragments, and hundreds of other proteins, compact into the dense inclusion body known as a Lewy body. Over 90% of the alpha-synuclein inside Lewy bodies carries a phosphorylation mark at serine-129 (pS129), compared to fewer than 4% of normal cellular protein.
What this actually means
The protein goes wrong in a step-by-step process: a single copy misfolds, copies stick together into small toxic clusters (oligomers), then grow into long fibres, and finally compact into dense clumps called Lewy bodies.
Picture this: Imagine a row of dominoes. One piece falls the wrong way, knocking its neighbour over, which knocks the next -- until you have a tangled pile. Each stage of the pile looks different and does different damage.
Why it matters: Different stages cause different kinds of harm, so treatments need to target the right stage. The small, early clusters (oligomers) appear to be the most toxic -- not the final large clumps.
The Misfolding Cascade
Misfolding does not happen all at once. It progresses through distinct stages, each with different structural properties and different degrees of toxicity. Understanding the sequence matters because different stages represent different therapeutic targets.
Healthy Monomer
In its normal state, alpha-synuclein is an intrinsically disordered 140-amino-acid protein (14.46 kDa) that adopts a loose, flexible structure. It concentrates at presynaptic terminals where it helps regulate vesicle release.
Early Misfolding
Under stress - oxidative damage, mutations, metal ions, or simply high local concentration - the monomer begins folding incorrectly, exposing hydrophobic regions normally tucked inside the structure.
Oligomers
Misfolded monomers cluster together into small, soluble oligomers of 10–50 units. This is widely considered the most neurotoxic stage: oligomers punch pores in cell membranes, disrupt calcium signalling, and impair mitochondria.
Protofibrils
Oligomers elongate into curved, ring-shaped or linear protofibrils. These structures begin acquiring the characteristic beta-sheet-rich core of mature amyloid fibrils and can still cross membranes.
Mature Fibrils
Protofibrils mature into straight, stable amyloid fibrils with a highly ordered beta-sheet spine. Fibrils are less acutely toxic than oligomers but serve as seeds for recruiting healthy protein into the misfolding cascade.
Lewy Body
Fibrils, along with lipids, organelle fragments, and hundreds of other proteins, compact into the dense inclusion body known as a Lewy body. Over 90% of the alpha-synuclein inside Lewy bodies carries a phosphorylation mark at serine-129 (pS129), compared to fewer than 4% of normal cellular protein.
Oligomers: The Real Toxic Species
For a long time, Lewy bodies were assumed to be the toxic agent - the obvious suspect because they were the most visible. But mounting evidence has pointed the finger at a much earlier, much smaller species: the soluble oligomers formed in steps 2 and 3.
Oligomers are dangerous for two main reasons. First, they can insert themselves into cell membranes and form ion-permeable pores, disrupting calcium homeostasis and triggering a cascade of oxidative damage. Second, they impair mitochondrial function - catastrophic for neurons whose high metabolic demands already make them vulnerable.
Membrane disruption
Alpha-synuclein oligomers form annular pore-like structures in lipid bilayers, allowing uncontrolled calcium influx and breaking down membrane potential.
Mitochondrial damage
Oligomers impair complex I of the mitochondrial respiratory chain, reducing ATP production and increasing reactive oxygen species in neurons that are already energetically stressed.
In animal models, expressing a version of alpha-synuclein locked into the oligomeric form causes neurodegeneration even without Lewy body formation. Conversely, some models show Lewy body formation without significant cell death. The oligomers, not the end-stage inclusions, are the prime suspects.
What this actually means
The small, early clumps of misfolded protein (oligomers) are the most damaging form -- not the large, visible Lewy bodies. Oligomers punch holes in cell walls and cripple the cell's power supply.
Picture this: Think of a leaky pipe. The big puddle on the floor (the Lewy body) is what you notice, but the real destruction comes from the tiny holes that are actively spraying water (the oligomers).
Why it matters: This changes the treatment target. Drugs aimed at dissolving the big clumps might miss the point -- the real danger is the small, mobile clusters doing damage right now.
Common misconception: Lewy bodies are not necessarily the 'killers.' They may actually be the brain's attempt to contain the toxic smaller clusters, like sealing hazardous waste in a drum.
Oligomers: The Real Toxic Species
For a long time, Lewy bodies were assumed to be the toxic agent - the obvious suspect because they were the most visible. But mounting evidence has pointed the finger at a much earlier, much smaller species: the soluble oligomers formed in steps 2 and 3.
Oligomers are dangerous for two main reasons. First, they can insert themselves into cell membranes and form ion-permeable pores, disrupting calcium homeostasis and triggering a cascade of oxidative damage. Second, they impair mitochondrial function - catastrophic for neurons whose high metabolic demands already make them vulnerable.
Membrane disruption
Alpha-synuclein oligomers form annular pore-like structures in lipid bilayers, allowing uncontrolled calcium influx and breaking down membrane potential.
Mitochondrial damage
Oligomers impair complex I of the mitochondrial respiratory chain, reducing ATP production and increasing reactive oxygen species in neurons that are already energetically stressed.
In animal models, expressing a version of alpha-synuclein locked into the oligomeric form causes neurodegeneration even without Lewy body formation. Conversely, some models show Lewy body formation without significant cell death. The oligomers, not the end-stage inclusions, are the prime suspects.
Lewy Bodies: Crime Scene, Not Cause of Death
A Lewy body is the equivalent of a sealed evidence bag at a crime scene: it tells you that something went badly wrong here, but the perpetrators - the soluble oligomers - have long since moved on.
One chemical fingerprint has proved remarkably consistent: more than 90% of the alpha-synuclein inside Lewy bodies carries a phosphate group at serine position 129 (pS129), compared to fewer than 4% of normal cellular alpha-synuclein. This phosphorylation mark may represent a cellular attempt to tag the misfolded protein for degradation - or it may promote aggregation. The exact role of pS129 is still debated.
Why this reframes treatment: If Lewy bodies are protective aggregates sequestering toxic oligomers, then dissolving them - without addressing the upstream misfolding - could actually worsen outcomes by releasing the toxic species back into the cytosol. Therapies must target the process that creates oligomers, not just the end-stage inclusions.
What this actually means
Lewy bodies are dense clumps found inside damaged brain cells. They are a marker that disease has been here, but the actual harm was done earlier by the smaller, soluble clusters (oligomers).
Picture this: A Lewy body is like the ash left after a fire. It tells you a fire happened, but the flames (the oligomers) already moved on to the next house.
Why it matters: Simply clearing away Lewy bodies without stopping the misfolding process could backfire by releasing trapped toxic material back into the cell.
Common misconception: For decades it was assumed Lewy bodies caused the damage. Current evidence suggests they may actually be a protective response -- the cell's attempt to wall off dangerous material.
Lewy Bodies: Crime Scene, Not Cause of Death
A Lewy body is the equivalent of a sealed evidence bag at a crime scene: it tells you that something went badly wrong here, but the perpetrators - the soluble oligomers - have long since moved on.
One chemical fingerprint has proved remarkably consistent: more than 90% of the alpha-synuclein inside Lewy bodies carries a phosphate group at serine position 129 (pS129), compared to fewer than 4% of normal cellular alpha-synuclein. This phosphorylation mark may represent a cellular attempt to tag the misfolded protein for degradation - or it may promote aggregation. The exact role of pS129 is still debated.
Why this reframes treatment: If Lewy bodies are protective aggregates sequestering toxic oligomers, then dissolving them - without addressing the upstream misfolding - could actually worsen outcomes by releasing the toxic species back into the cytosol. Therapies must target the process that creates oligomers, not just the end-stage inclusions.
Prion-Like Spread
One of the most consequential discoveries in Parkinson's research is that alpha-synuclein pathology does not stay where it starts. It spreads - in a pattern eerily reminiscent of prion diseases - from neuron to neuron, following predictable anatomical routes through the brain.
Unlike true prions, misfolded alpha-synuclein does not cause a rapidly fatal illness. But the underlying mechanism is analogous: a misfolded template contacts a healthy protein and induces it to adopt the wrong shape. Three routes of spread have been characterised:
Exosomes
Neurons package misfolded alpha-synuclein into small membrane-bound vesicles (exosomes) and release them into the extracellular space. Nearby cells can take up these vesicles, importing the misfolded template and seeding new aggregation.
Tunneling Nanotubes
Stressed neurons can extend thin cytoplasmic bridges - tunneling nanotubes - that physically connect to neighbouring cells. Aggregates can travel directly through these tubes, bypassing the extracellular space entirely.
LAG3 Receptor
Research has identified LAG3 (lymphocyte-activation gene 3) as a receptor on neuronal surfaces that binds alpha-synuclein fibrils with high affinity, mediating their endocytosis. Blocking LAG3 in animal models reduces cell-to-cell spread.
What this actually means
The misfolded protein does not stay in one place. It escapes from sick cells and enters healthy ones, corrupting the proteins there too. It travels via tiny bubbles (exosomes), direct cell-to-cell tunnels, and specific docking ports on the cell surface.
Picture this: Imagine a rumour spreading through a school. One person whispers it to a neighbour, who whispers it to another -- except here, each person who hears the rumour changes their behaviour. The 'rumour' is the wrong protein shape, and it travels along the brain's wiring.
Why it matters: This spreading explains why Parkinson's gets worse over time and why new brain regions become affected. It also means future treatments might try to block these spreading routes.
Common misconception: Alpha-synuclein is 'prion-like' but is not a true prion. It does not cause the rapid, fatal brain diseases that prions do -- it spreads much more slowly over years to decades.
Prion-Like Spread
One of the most consequential discoveries in Parkinson's research is that alpha-synuclein pathology does not stay where it starts. It spreads - in a pattern eerily reminiscent of prion diseases - from neuron to neuron, following predictable anatomical routes through the brain.
Unlike true prions, misfolded alpha-synuclein does not cause a rapidly fatal illness. But the underlying mechanism is analogous: a misfolded template contacts a healthy protein and induces it to adopt the wrong shape. Three routes of spread have been characterised:
Exosomes
Neurons package misfolded alpha-synuclein into small membrane-bound vesicles (exosomes) and release them into the extracellular space. Nearby cells can take up these vesicles, importing the misfolded template and seeding new aggregation.
Tunneling Nanotubes
Stressed neurons can extend thin cytoplasmic bridges - tunneling nanotubes - that physically connect to neighbouring cells. Aggregates can travel directly through these tubes, bypassing the extracellular space entirely.
LAG3 Receptor
Research has identified LAG3 (lymphocyte-activation gene 3) as a receptor on neuronal surfaces that binds alpha-synuclein fibrils with high affinity, mediating their endocytosis. Blocking LAG3 in animal models reduces cell-to-cell spread.
The Strain Hypothesis: One Protein, Many Diseases
A single protein - alpha-synuclein - is central to at least three distinct diseases: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Why does the same protein produce such different clinical pictures?
The leading explanation, borrowed again from prion biology, is the strain hypothesis. Different misfolding conformations - different three-dimensional folds of the same amino acid sequence - may give rise to aggregates with distinct structural properties, distinct cellular tropisms (which cell types they prefer), and distinct rates of spread.
PD
Parkinson's disease
Primarily neurons (SNc, then cortex)
DLB
Dementia with Lewy bodies
Neurons - cortex predominant from early stages
MSA
Multiple System Atrophy
Oligodendrocytes - glial cytoplasmic inclusions
In MSA, alpha-synuclein aggregates primarily in oligodendrocytes rather than neurons, and the fibrils have a measurably different structure from those in PD. If confirmed, this means the strain of alpha-synuclein present in a patient's brain may one day become a diagnostic and prognostic biomarker.
What this actually means
The same protein can misfold into different shapes, and each shape causes a different disease. This 'strain' idea may explain why some people get Parkinson's, others get a form of dementia, and others get a rarer condition called MSA.
Picture this: Think of the same sheet of paper being crumpled in three different ways. Each crumple pattern creates a different shape that sticks to different surfaces -- one shape sticks to neurons, another to brain support cells.
Why it matters: If doctors could identify which 'strain' a patient has, they might be able to predict how the disease will progress and choose targeted treatments.
The Strain Hypothesis: One Protein, Many Diseases
A single protein - alpha-synuclein - is central to at least three distinct diseases: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Why does the same protein produce such different clinical pictures?
The leading explanation, borrowed again from prion biology, is the strain hypothesis. Different misfolding conformations - different three-dimensional folds of the same amino acid sequence - may give rise to aggregates with distinct structural properties, distinct cellular tropisms (which cell types they prefer), and distinct rates of spread.
PD
Parkinson's disease
Primarily neurons (SNc, then cortex)
DLB
Dementia with Lewy bodies
Neurons - cortex predominant from early stages
MSA
Multiple System Atrophy
Oligodendrocytes - glial cytoplasmic inclusions
In MSA, alpha-synuclein aggregates primarily in oligodendrocytes rather than neurons, and the fibrils have a measurably different structure from those in PD. If confirmed, this means the strain of alpha-synuclein present in a patient's brain may one day become a diagnostic and prognostic biomarker.
The Transplant Evidence
The most striking evidence for cell-to-cell spread came from an unexpected source: patients who had received transplants of healthy foetal dopamine neurons as an experimental therapy in the 1980s and 1990s.
When these patients died - of unrelated causes - and their brains were examined post-mortem, researchers Jeffery Kordower and Patrik Brundin (working with Olle Lindvall) reported in 2008 that the transplanted neurons, which had been alive and functional for 10 to 16 years, had developed Lewy body pathology.
Kordower / Li et al., 2008
Foetal neurons transplanted into a diseased PD brain - neurons that were genetically normal and had no inherited predisposition to aggregate alpha-synuclein - acquired Lewy body pathology after 10–16 years. The disease had, in effect, spread from the host brain into the graft.
This finding was independently reported by two groups simultaneously and has been replicated in subsequent transplant autopsies. It provided the first direct human evidence that alpha-synuclein pathology can propagate from diseased host neurons to healthy transplanted neurons - transforming the spread hypothesis from a laboratory curiosity into a clinical reality with profound implications for any cell replacement strategy.
What this actually means
When healthy young neurons were transplanted into Parkinson's patients' brains, those healthy cells eventually caught the disease from their neighbours -- proving that the misfolded protein can spread from sick cells to healthy ones in humans.
Picture this: Imagine moving a healthy plant into a garden with a soil fungus. Over years, the fungus creeps into the new plant too. The transplanted neurons were the healthy plant, and the misfolded protein was the fungus.
Why it matters: This proves that Parkinson's actively spreads between cells. It also means any future cell transplant therapy must account for this spreading, or the new cells will eventually get sick too.
The Transplant Evidence
The most striking evidence for cell-to-cell spread came from an unexpected source: patients who had received transplants of healthy foetal dopamine neurons as an experimental therapy in the 1980s and 1990s.
When these patients died - of unrelated causes - and their brains were examined post-mortem, researchers Jeffery Kordower and Patrik Brundin (working with Olle Lindvall) reported in 2008 that the transplanted neurons, which had been alive and functional for 10 to 16 years, had developed Lewy body pathology.
Kordower / Li et al., 2008
Foetal neurons transplanted into a diseased PD brain - neurons that were genetically normal and had no inherited predisposition to aggregate alpha-synuclein - acquired Lewy body pathology after 10–16 years. The disease had, in effect, spread from the host brain into the graft.
This finding was independently reported by two groups simultaneously and has been replicated in subsequent transplant autopsies. It provided the first direct human evidence that alpha-synuclein pathology can propagate from diseased host neurons to healthy transplanted neurons - transforming the spread hypothesis from a laboratory curiosity into a clinical reality with profound implications for any cell replacement strategy.
Key Takeaway
What Scientists Know vs. What's Still Uncertain
Established
- Alpha-synuclein is 140 amino acids, 14.46 kDa, and constitutes ~1% of cytosolic brain protein.
- Misfolding follows a monomer → oligomer → protofibril → fibril → Lewy body sequence.
- Over 90% of alpha-synuclein in Lewy bodies is pS129-phosphorylated, vs. under 4% normally.
- Transplanted neurons developed Lewy body pathology after 10–16 years (Kordower/Li 2008).
- LAG3 receptor mediates fibril endocytosis; exosomes and tunneling nanotubes mediate spread.
Still Uncertain
- Whether pS129 phosphorylation drives aggregation or is a downstream response to it remains unresolved.
- Whether Lewy bodies are protective (sequestering toxic oligomers) or harmful remains actively debated.
- The structural basis of different "strains" and whether they reliably predict clinical phenotype (PD vs DLB vs MSA) requires further validation in human cohorts.
- Whether blocking spread mechanisms (e.g., anti-LAG3 strategies) will translate to meaningful clinical benefit is not yet proven in human trials.